Article Text

other Versions

Screening for Familial Ovarian Cancer: Poor survival of BRCA1/2 related cancers
  1. Gareth R Evans (gareth.evans{at}
  1. St Mary's Manchester, United Kingdom
    1. Katja N Gaarenstroom
    1. Leiden University Medical Center, Netherlands
      1. Diane stirling (diane.stirling{at}
      1. Western General Hospital, United Kingdom
        1. Andrew Shenton (andrew.shenton{at}
        1. St Mary's Manchester, United Kingdom
          1. lovise Maehle (l.o.mahle{at}
          1. Rikshospitalet Radiumhospitalet, Norway
            1. Ann Dørum (anne.dorum{at}
            1. Rikshospitalet Radiumhospitalet, Norway
              1. Michael Steel (mandjsteel{at}
              1. University of St Andrews, United Kingdom
                1. Fiona Lalloo (fiona.lalloo{at}
                1. St Marys Hospital, Manchester, United Kingdom
                  1. Jaran Apold (jaran.apold{at}
                  1. Haukeland University Hospital, Norway
                    1. Mary Porteous (mary.porteous{at}
                    1. SE Scotlang Genetic Service, United Kingdom
                      1. Hans F.A. Vasen (hfavasen{at}
                      1. Netherlands Foundation for the Detection of Hereditary Tumours, Netherlands
                        1. Christi van Asperen (c.j.van_asperen{at}
                        1. Leiden University Medical Center, Netherlands
                          1. Pal Moller (pal.moller{at}
                          1. Rikshospitalet Radiumhospitalet, Norway


                            Purpose: To assess the effectiveness of annual ovarian cancer screening (transvaginal ultrasound and serum CA125 estimation) in reducing mortality from ovarian cancer in women at increased genetic risk.

                            Patients and methods: A cohort of 3532 women at increased risk of ovarian cancer was screened at five European centres between January 1991 and March 2007. Survival from diagnosis of ovarian cancer was calculated using Kaplan-Meier analysis and compared for proven BRCA1/2 carriers with non-carriers and whether the cancer was detected at prevalence or post prevalent scan. Screening was performed by annual transvaginal ultrasound and serum CA125 measurement

                            Results: 64 epithelial ovarian malignancies (59 invasive and 5 borderline), developed in the cohort. 26 tumours were detected at prevalent round, there were 27 incident detected cancers and 11 interval. Sixty-five percent of cancers were stage 3 or 4, however, stage and survival were little different for prevalent versus post prevalent cancers. Five year and 10-year survival in 49 BRCA1/2 mutation carriers was 58.6% (95% CI 50.9-66.3%) and 36% (95% CI 27-45%), which was significantly worse than for 15 non BRCA-carriers (91.8% (95% CI 84-99.6%) both 5 and 10-year survival p=0.015). However, when borderline tumours were excluded, the difference in survival between carriers and non-carriers was no longer significant.

                            Conclusion: Annual surveillance, by trans-vaginal ultrasound scanning and serum CA125 measurement in women at increased familial risk of ovarian cancer is ineffective in detecting tumours at a sufficiently early stage to substantially influence survival in BRCA1/2 carriers.

                            Statistics from

                            Request permissions

                            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.